Ann K Daly

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5899205/publications.pdf

Version: 2024-02-01

280 papers	28,911 citations	4370 86 h-index	5806 161 g-index
324 all docs	324 docs citations	324 times ranked	20108 citing authors

#	Article	IF	Citations
1	Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nature Genetics, 2001, 27, 383-391.	9.4	1,954
2	Estimation of the Warfarin Dose with Clinical and Pharmacogenetic Data. New England Journal of Medicine, 2009, 360, 753-764.	13.9	1,375
3	Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet, The, 1999, 353, 717-719.	6.3	1,181
4	HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nature Genetics, 2009, 41, 816-819.	9.4	950
5	The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood, 2005, 106, 2329-2333.	0.6	894
6	Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology and Therapeutics, 2011, 89, 806-815.	2.3	773
7	A Randomized Trial of Genotype-Guided Dosing of Warfarin. New England Journal of Medicine, 2013, 369, 2294-2303.	13.9	735
8	NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature, 2021, 592, 450-456.	13.7	649
9	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
10	TM6SF2 rs58542926 influences hepatic fibrosis progression in patients with non-alcoholic fatty liver disease. Nature Communications, 2014, 5, 4309.	5.8	478
11	Carriage of the PNPLA3 rs738409 C >G polymorphism confers an increased risk of non-alcoholic fatty liver disease associated hepatocellular carcinoma. Journal of Hepatology, 2014, 61, 75-81.	1.8	431
12	Susceptibility to Amoxicillin-Clavulanate-Induced Liver Injury Is Influenced by Multiple HLA Class I and II Alleles. Gastroenterology, 2011, 141, 338-347.	0.6	412
13	Nomenclature for human CYP2D6 alleles. Pharmacogenetics and Genomics, 1996, 6, 193-201.	5.7	403
14	Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clinical Pharmacology and Therapeutics, 2005, 77, 468-478.	2.3	320
15	Genetic Susceptibility to Diclofenac-Induced Hepatotoxicity: Contribution of UGT2B7, CYP2C8, and ABCC2 Genotypes. Gastroenterology, 2007, 132, 272-281.	0.6	318
16	Association of a tumor necrosis factor promoter polymorphism with susceptibility to alcoholic steatohepatitis. Hepatology, 1997, 26, 143-146.	3.6	315
17	Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics and Genomics, 2002, 12, 121-132.	5.7	295
18	The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics and Genomics, 2001, 11, 555-572.	5.7	293

#	Article	IF	Citations
19	Genome-wide association study of non-alcoholic fatty liver and steatohepatitis in a histologically characterised cohortâ˜†. Journal of Hepatology, 2020, 73, 505-515.	1.8	279
20	Impact of cytochrome P450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients1 2. Transplantation, 2003, 76, 1233-1235.	0.5	257
21	Meta- and pooled analyses of the effects of glutathione S-transferase M1 polymorphisms and smoking on lung cancer risk. Carcinogenesis, 2002, 23, 1343-1350.	1.3	250
22	Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet, The, 1992, 339, 1017-1018.	6.3	248
23	Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology. Pharmacogenetics and Genomics, 1995, 5, 215-223.	5.7	248
24	Genome-wide association studies in pharmacogenomics. Nature Reviews Genetics, 2010, 11, 241-246.	7.7	238
25	The role of individual human cytochrpmes P450 in drug metabolism and clinical response. Trends in Pharmacological Sciences, 1992, 13, 434-439.	4.0	229
26	CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6Î±-hydroxylase activity in human liver microsomes. Biochemical Pharmacology, 2002, 64, 1579-1589.	2.0	224
27	Pharmacogenetics of Tardive Dyskinesia Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism. Neuropsychopharmacology, 2002, 27, 105-119.	2.8	217
28	Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity. Hepatology, 2004, 39, 1430-1440.	3.6	216
29	Human leukocyte antigen (HLA)-B*57:01-restricted activation of drug-specific T cells provides the immunological basis for flucloxacillin-induced liver injury. Hepatology, 2013, 57, 727-739.	3.6	212
30	Pooled Analysis and Meta-analysis of Glutathione S-Transferase M1 and Bladder Cancer: A HuGE Review. American Journal of Epidemiology, 2002, 156, 95-109.	1.6	209
31	Heterozygosity for hereditary hemochromatosis is associated with more fibrosis in chronic hepatitis C. Hepatology, 1998, 27, 1695-1699.	3.6	205
32	Significance of the Minor Cytochrome P450 3A Isoforms. Clinical Pharmacokinetics, 2006, 45, 13-31.	1.6	205
33	Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis. Science Translational Medicine, 2020, 12, .	5.8	205
34	Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clinical Pharmacology and Therapeutics, 2004, 75, 204-212.	2.3	183
35	Ultrarapid metabolizers of debrisoquine: Characterization and PCR-based detection of alleles with duplication of theCYP2D6gene. FEBS Letters, 1996, 392, 30-34.	1.3	181
36	CYP2E1 Genetic Polymorphisms and Risk of Nasopharyngeal Carcinoma in Taiwan. Journal of the National Cancer Institute, 1997, 89, 1207-1212.	3.0	178

#	Article	IF	Citations
37	Pharmacogenetics of oral anticoagulants. Pharmacogenetics and Genomics, 2003, 13, 247-252.	5.7	177
38	Association of Liver Injury From Specific Drugs, or Groups ofÂDrugs, With Polymorphisms in HLA and Other Genes in aÂGenome-Wide Association Study. Gastroenterology, 2017, 152, 1078-1089.	0.6	174
39	Metabolic polymorphisms. , 1993, 57, 129-160.		172
40	CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clinical Pharmacology and Therapeutics, 2004, 75, 422-433.	2.3	171
41	Enhanced liver fibrosis test for the non-invasive diagnosis of fibrosis in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2020, 73, 252-262.	1.8	170
42	CTLA-4 gene polymorphism confers susceptibility to primary biliary cirrhosis. Journal of Hepatology, 2000, 32, 538-541.	1.8	169
43	Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundamental and Clinical Pharmacology, 2003, 17, 27-41.	1.0	167
44	Interleukin 10 promoter region polymorphisms and susceptibility to advanced alcoholic liver disease. Gut, 2000, 46, 540-545.	6.1	156
45	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156
46	Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide. Clinical Pharmacology and Therapeutics, 2003, 74, 380-387.	2.3	154
47	Identification of human cytochrome P450 isoforms that contribute to all-trans-retinoic acid 4-hydroxylation. Biochemical Pharmacology, 2000, 60, 517-526.	2.0	150
48	Diagnostic accuracy of elastography and magnetic resonance imaging in patients with NAFLD: A systematic review and meta-analysis. Journal of Hepatology, 2021, 75, 770-785.	1.8	149
49	Genetic variants regulating insulin receptor signalling are associated with the severity of liver damage in patients with non-alcoholic fatty liver disease. Gut, 2010, 59, 267-273.	6.1	148
50	Pharmacogenetic allele nomenclature: International workgroup recommendations for test result reporting. Clinical Pharmacology and Therapeutics, 2016, 99, 172-185.	2.3	146
51	Candidate gene case-control association studies: advantages and potential pitfalls. British Journal of Clinical Pharmacology, 2001, 52, 489-499.	1.1	141
52	Genetic variation of CYP2A6, smoking, and risk of cancer. Lancet, The, 1999, 353, 898-899.	6.3	137
53	Variation in induced CYP1A1 levels: relationship to CYP1A1, Ah receptor and GSTM1 polymorphisms. Pharmacogenetics and Genomics, 2000, 10, 11-24.	5.7	137
54	Human leucocyte antigen class II genotype in susceptibility and resistance to co-amoxiclav-induced liver injury. Journal of Hepatology, 2010, 53, 1049-1053.	1.8	137

#	Article	IF	Citations
55	Pharmacogenomics of CYP2C9: Functional and Clinical Considerations. Journal of Personalized Medicine, 2018, 8, 1.	1.1	136
56	Weight Loss Decreases Excess Pancreatic Triacylglycerol Specifically in Type 2 Diabetes. Diabetes Care, 2016, 39, 158-165.	4.3	135
57	Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics, 2009, 10, 1687-1695.	0.6	131
58	Polymorphism of Glutathione S-Transferase M1 and Lung Cancer Risk Among African-Americans and Caucasians in Los Angeles County, California. Journal of the National Cancer Institute, 1995, 87, 1246-1253.	3.0	126
59	PNPLA3 Gene Polymorphism Is Associated With Predisposition to and Severity of Alcoholic Liver Disease. American Journal of Gastroenterology, 2015, 110, 846-856.	0.2	120
60	[22] CYP2D6 multiallelism. Methods in Enzymology, 1996, 272, 199-210.	0.4	117
61	Identification of the major human hepatic cytochrome P450 involved in activation and N-dechloroethylation of ifosfamide. Biochemical Pharmacology, 1994, 47, 1157-1163.	2.0	113
62	Pharmacogeneticâ€guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon. British Journal of Clinical Pharmacology, 2014, 77, 626-641.	1.1	113
63	Pharmacogenetics of the Cytochromes P450. Current Topics in Medicinal Chemistry, 2004, 4, 1733-1744.	1.0	112
64	Tumour necrosis factor-alpha gene promoter polymorphism and decreased insulin resistance. Diabetologia, 1998, 41, 430-434.	2.9	111
65	CYP2D6 phenotype ??? genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics and Genomics, 1998, 8, 529-542.	5.7	111
66	Relationship between acetylator status, smoking, and diet and colorectal cancer risk in the north-east of England. Carcinogenesis, 1997, 18, 1351-1354.	1.3	109
67	Limited contribution of common genetic variants to risk for liver injury due to a variety of drugs. Pharmacogenetics and Genomics, 2012, 22, 784-795.	0.7	108
68	Genetic and metabolic criteria for the assignment of debrisoquine 4-hydroxylation (cytochrome) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 2	5.7	106
69	Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics and Genomics, 2000, 10, 511-518.	5.7	105
70	Polymorphisms in CYP2D6 duplication-negative individuals with the ultrarapid metabolizer phenotype: a role for the CYP2D6*35 allele in ultrarapid metabolism?. Pharmacogenetics and Genomics, 2001, 11, 45-55.	5.7	101
71	Genetics of Alcoholic and Nonalcoholic Fatty Liver Disease. Seminars in Liver Disease, 2011, 31, 128-146.	1.8	101
72	Genetic Basis of Drug-Induced Liver Injury: Present and Future. Seminars in Liver Disease, 2014, 34, 123-133.	1.8	101

#	Article	IF	Citations
73	Genetic association studies in drug-induced liver injury. Drug Metabolism Reviews, 2012, 44, 116-126.	1.5	100
74	Using Genome-Wide Association Studies to Identify Genes Important in Serious Adverse Drug Reactions. Annual Review of Pharmacology and Toxicology, 2012, 52, 21-35.	4.2	100
75	Minocycline hepatotoxicity: Clinical characterization and identification of HLA-Bâˆ—35:02 as a risk factor. Journal of Hepatology, 2017, 67, 137-144.	1.8	100
76	Detection and characterization of novel polymorphisms in the CYP2E1 gene. Pharmacogenetics and Genomics, 1998, 8, 543-552.	5.7	99
77	VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood, 2012, 119, 868-873.	0.6	99
78	Genetic Association Studies in Drug-Induced Liver Injury. Seminars in Liver Disease, 2009, 29, 400-411.	1.8	98
79	Molecular basis of polymorphic drug metabolism. Journal of Molecular Medicine, 1995, 73, 539-53.	1.7	97
80	A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury. Gastroenterology, 2019, 156, 1707-1716.e2.	0.6	97
81	An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians. Pharmacogenetics and Genomics, 1998, 8, 129-136.	5.7	95
82	Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype. British Journal of Psychiatry, 1997, 170, 23-26.	1.7	94
83	The RsaI polymorphism of CYP2E1 and susceptibility to alcoholic liver disease in Caucasians: effect on age of presentation and dependence on alcohol dehydrogenase genotype. Pharmacogenetics and Genomics, 1998, 8, 335-342.	5.7	94
84	GENETIC EPIDEMIOLOGY OF ENVIRONMENTAL TOXICITY AND CANCER SUSCEPTIBILITY: HUMAN ALLELIC POLYMORPHISMS IN DRUG-METABOLIZING ENZYME GENES, THEIR FUNCTIONAL IMPORTANCE, AND NOMENCLATURE ISSUES. Drug Metabolism Reviews, 1999, 31, 467-487.	1.5	92
85	Pharmacogenetics and human genetic polymorphisms. Biochemical Journal, 2010, 429, 435-449.	1.7	91
86	Role of glutathioneS-transferase P1, P-glycoprotein and multidrug resistance-associated protein 1 in acquired doxorubicin resistance. International Journal of Cancer, 2001, 92, 777-783.	2.3	88
87	Interphase nuclear matrix and metaphase scaffolding structures. Journal of Cell Science, 1984, 1984, 103-122.	1.2	87
88	Upstream and coding region CYP2C9 polymorphisms. Pharmacogenetics and Genomics, 2004, 14, 813-822.	5.7	87
89	Pharmacogenomics of adverse drug reactions. Genome Medicine, 2013, 5, 5.	3.6	87
90	Heterozygotes for HFE mutations have no increased risk of advanced alcoholic liver disease. Gut, 1998, 43, 262-266.	6.1	86

#	Article	IF	Citations
91	Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. European Heart Journal, 2011, 32, 1909-1917.	1.0	86
92	Clinical and Pharmacogenetic Influences on Response to Hydroxychloroquine in Discoid Lupus Erythematosus: A Retrospective Cohort Study. Journal of Investigative Dermatology, 2011, 131, 1981-1986.	0.3	84
93	Evidence that a polymorphism within the 3â€²UTR of glutathione peroxidase 4 is functional and is associated with susceptibility to colorectal cancer. Genes and Nutrition, 2007, 2, 225-232.	1.2	83
94	Characterization of amoxicillinâ€•and clavulanic acidâ€•specific T cells in patients with amoxicillinâ€•clavulanateâ€“induced liver injury. Hepatology, 2015, 62, 887-899.	3.6	83
95	Tumour necrosis factor-a promoter polymorphisms in primary biliary cirrhosis. Journal of Hepatology, 1999, 30, 232-236.	1.8	79
96	Polymorphisms of the CYP2D6 gene increase susceptibility to ankylosing spondylitis. Human Molecular Genetics, 2000, 9, 1563-1566.	1.4	79
97	Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California. Pharmacogenetics and Genomics, 1996, 6, 527-533.	5.7	77
98	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	1.8	77
99	Cytochrome P450 CYP1B1 and catechol O -methyltransferase (COMT) genetic polymorphisms and breast cancer susceptibility in a Turkish population. Archives of Toxicology, 2002, 76, 643-649.	1.9	76
100	TM6SF2: Catch-22 in the Fight Against Nonalcoholic Fatty Liver Disease and Cardiovascular Disease?. Gastroenterology, 2015, 148, 679-684.	0.6	75
101	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NFÂB signalling pathways. Annals of the Rheumatic Diseases, 2010, 69, 1315-1320.	0.5	74
102	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
103	PharmVar GeneFocus: CYP2C19. Clinical Pharmacology and Therapeutics, 2021, 109, 352-366.	2.3	72
104	Transcriptomics Identify Thrombospondinâ€2 as a Biomarker for NASH and Advanced Liver Fibrosis. Hepatology, 2021, 74, 2452-2466.	3.6	71
105	Lung cancer risk in relation to genetic polymorphisms of microsomal epoxide hydrolase among African-Americans and Caucasians in Los Angeles County. Lung Cancer, 2000, 28, 147-155.	0.9	70
106	The population pharmacokinetics of Râ€•and Sâ€warfarin: effect of genetic and clinical factors. British Journal of Clinical Pharmacology, 2012, 73, 66-76.	1.1	70
107	Oral anticoagulation: a critique of recent advances and controversies. Trends in Pharmacological Sciences, 2015, 36, 153-163.	4.0	70
108	Paracetamol metabolism, hepatotoxicity, biomarkers and therapeutic interventions: a perspective. Toxicology Research, 2018, 7, 347-357.	0.9	70

#	Article	IF	Citations
109	Drug-induced liver injury: past, present and future. Pharmacogenomics, 2010, 11, 607-611.	0.6	69
110	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
111	Genetic polymorphism of CYP2D6 and lung cancer risk in African- Americans and Caucasians in Los Angeles County. Carcinogenesis, 1997, 18, 1203-1214.	1.3	66
112	Human cytochrome P450 (CYP) genes: recommendations for the nomenclature of alleles. Pharmacogenetics and Genomics, 2000, 10, 91-93.	5.7	66
113	CYP3A5 phenotype-genotype correlations in a British population. British Journal of Clinical Pharmacology, 2003, 55, 625-629.	1.1	65
114	Poor metabolisers of nicotine and CYP2D6 polymorphism. Lancet, The, 1994, 343, 62-63.	6.3	64
115	HLA-DRB1*16. Pharmacogenetics and Genomics, 2016, 26, 218-224.	0.7	63
116	Genetic and epigenetic factors in autoimmune reactions toward cytochrome P4502E1 in alcoholic liver disease. Hepatology, 2003, 37, 410-419.	3.6	61
117	The Phenotype Standardization Project: Improving Pharmacogenetic Studies of Serious Adverse Drug Reactions. Clinical Pharmacology and Therapeutics, 2011, 89, 784-785.	2.3	61
118	The pharmacogenetics of chemical carcinogenesis. Pharmacogenetics and Genomics, 1992, 2, 246-258.	5.7	59
119	Genetic modifiers of non-alcoholic fatty liver disease progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2011, 1812, 1557-1566.	1.8	59
120	Lung cancer risk in relation to nicotinic acetylcholine receptor, CYP2A6 and CYP1A1 genotypes in the Bangladeshi population. Clinica Chimica Acta, 2013, 416, 11-19.	0.5	58
121	Drugâ€Induced Liver Injury due to Flucloxacillin: Relevance of Multiple Human Leukocyte Antigen Alleles. Clinical Pharmacology and Therapeutics, 2019, 106, 245-253.	2.3	58
122	Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenetics and Genomics, 2009, 19, 800-812.	0.7	57
123	N-acetyltransferase 2 (NAT2) genotype as a risk factor for development of drug-induced liver injury relating to antituberculosis drug treatment in a mixed-ethnicity patient group. European Journal of Clinical Pharmacology, 2014, 70, 1079-1086.	0.8	56
124	A role for the pregnane X receptor in flucloxacillin-induced liver injury. Hepatology, 2010, 51, 1656-1664.	3.6	55
125	Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nature Medicine, 2020, 26, 1541-1548.	15.2	55
126	The cytochrome P450 CYP2D6 allelic variant CYP 2D6J and related polymorphisms in a European population. Pharmacogenetics and Genomics, 1994, 4, 73-81.	5.7	55

#	Article	IF	Citations
127	Gene polymorphisms of cellular senescence marker p21 and disease progression in non-alcohol-related fatty liver disease. Cell Cycle, 2014, 13, 1489-1494.	1.3	54
128	Genomeâ€wide Association Study and Metaâ€analysis on Alcoholâ€Associated Liver Cirrhosis Identifies Genetic Risk Factors. Hepatology, 2021, 73, 1920-1931.	3.6	54
129	Macrophage scavenger receptor 1 mediates lipid-induced inflammation in non-alcoholic fatty liver disease. Journal of Hepatology, 2022, 76, 1001-1012.	1.8	54
130	Characterization and PCR-based detection of two different hybrid CYP2D7P/CYP2D6 alleles associated with the poor metabolizer phenotype??. Pharmacogenetics and Genomics, 1996, 6, 319-328.	5.7	53
131	Relationship between genotype for the cytochrome P450 CYP2D6 and susceptibility to ankylosing spondylitis and rheumatoid arthritis.. Annals of the Rheumatic Diseases, 1996, 55, 66-68.	0.5	53
132	Recent advances in understanding the molecular basis of polymorphisms in genes encoding cytochrome P450 enzymes. Toxicology Letters, 1998, 102-103, 143-147.	0.4	53
133	Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. Expert Review of Gastroenterology and Hepatology, 2011, 5, 253-263.	1.4	53
134	Shared Genetic Risk Factors Across Carbamazepineâ€Induced Hypersensitivity Reactions. Clinical Pharmacology and Therapeutics, 2019, 106, 1028-1036.	2.3	52
135	Detailed modelling of caffeine metabolism and examination of the CYP1A2 gene. Pharmacogenetics and Genomics, 1999, 9, 367-376.	5.7	50
136	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology, 2002, 36, 1355-1360.	3.6	50
137	Optimal dosing of warfarin and other coumarin anticoagulants: the role of genetic polymorphisms. Archives of Toxicology, 2013, 87, 407-420.	1.9	50
138	Lung cancer risk in relation to the CYP2E1 Rsa I genetic polymorphism among African-Americans and Caucasians in Los Angeles County. Pharmacogenetics and Genomics, 1996, 6, 151-158.	5.7	48
139	CYP2D6 is associated with Parkinson??s disease but not with dementia with Lewy Bodies or Alzheimer??s disease. Pharmacogenetics and Genomics, 1999, 9, 31-36.	5.7	48
140	Pharmacogenetics: a general review on progress to date. British Medical Bulletin, 2017, 124, 1-15.	2.7	48
141	Low frequency of CYP2A6 gene polymorphism as revealed by a one-step polymerase chain reaction method. Pharmacogenetics and Genomics, 1999, 9, 327-332.	5.7	46
142	Association of single nucleotide polymorphisms in the interleukin-4 gene and interleukin-4 receptor gene with Crohnâ€™s disease in a British population. Genes and Immunity, 2001, 2, 44-47.	2.2	46
143	APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenetics and Genomics, 2006, 16, 609-611.	0.7	46
144	Adaptive Dosing Approaches to the Individualization of 13-Cis-Retinoic Acid (Isotretinoin) Treatment for Children with High-Risk Neuroblastoma. Clinical Cancer Research, 2013, 19, 469-479.	3.2	45

#	Article	IF	Citations
145	A common polymorphism in theABCB11gene is associated with advanced fibrosis in hepatitis C but not in non-alcoholic fatty liver disease. Clinical Science, 2011, 120, 287-296.	1.8	44
146	Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease. Cancer Medicine, 2017, 6, 1930-1940.	1.3	43
147	Human Leukocyte Antigen B*14:01 and B*35:01 Are Associated With Trimethoprimâ€Sulfamethoxazole Induced Liver Injury. Hepatology, 2021, 73, 268-281.	3.6	43
148	Stereoselective cardiotoxic effects of terodiline. Clinical Pharmacology and Therapeutics, 1996, 60, 89-98.	2.3	41
149	Role of polymorphisms in the interleukin-10 gene in determining disease susceptibility and phenotype in inflamatory bowel disease. Digestive Diseases and Sciences, 2001, 46, 1520-1525.	1.1	41
150	Promiscuous T-cell responses to drugs and drug-haptens. Journal of Allergy and Clinical Immunology, 2015, 136, 474-476.e8.	1.5	41
151	A multi-factorial analysis of response to warfarin in a UK prospective cohort. Genome Medicine, 2016, 8, 2.	3.6	41
152	Homozygosity for the Gly-9 variant of the dopamine D3 receptor and risk for tardive dyskinesia in schizophrenic patients. International Journal of Neuropsychopharmacology, 2000, 3, 61-65.	1.0	40
153	Inter-individual variation in nucleotide excision repair in young adults: effects of age, adiposity, micronutrient supplementation and genotype. British Journal of Nutrition, 2009, 101, 1316.	1.2	40
154	Inter-individual variation in DNA damage and base excision repair in young, healthy non-smokers: effects of dietary supplementation and genotype. British Journal of Nutrition, 2010, 103, 1585-1593.	1.2	40
155	Do multiple cytochrome P450 isoforms contribute to parathion metabolism in man?. Archives of Toxicology, 2003, 77, 313-320.	1.9	39
156	Genetics of Alcoholic Liver Disease. Seminars in Liver Disease, 2015, 35, 361-374.	1.8	39
157	Characterisation of a retinoic-acid-binding component from F9 embryonal-carcinoma-cell nuclei. FEBS Journal, 1987, 168, 133-139.	0.2	37
158	Lung cancer risk in relation to the CYP2C9 genetic polymorphism among Caucasians in Los Angeles County. Pharmacogenetics and Genomics, 1997, 7, 401-404.	5.7	37
159	An inactive cytochrome P450 CYP2D6 allele containing a deletion and a base substitution. Human Genetics, 1995, 95, 337-41.	1.8	36
160	Comparison of substrate metabolism by wild type CYP2D6 protein and a variant containing methionine, not valine, at position 374. Pharmacogenetics and Genomics, 1995, 5, 234-243.	5.7	35
161	Genetic polymorphism of manganese superoxide dismutase (MnSOD) and breast cancer susceptibility. Cell Biochemistry and Function, 2005, 23, 73-76.	1.4	35
162	Influence of IL-6, COL1A1, and VDR gene polymorphisms on bone mineral density in Crohn's disease. Gut, 2005, 54, 1579-1584.	6.1	35

#	Article	IF	Citations
163	Genetic Polymorphisms Affecting Drug Metabolism. Advances in Pharmacology, 2012, 63, 137-167.	1.2	35
164	No evidence for involvement of the interleukin-10 â^'592 promoter polymorphism in genetic susceptibility to primary biliary cirrhosis. Journal of Hepatology, 1998, 28, 820-823.	1.8	34
165	Polymorphic Variants of Cytochrome P450. Advances in Pharmacology, 2015, 74, 85-111.	1.2	34
166	PharmVar GeneFocus: CYP2C9. Clinical Pharmacology and Therapeutics, 2021, 110, 662-676.	2.3	34
167	CYP2D6 deficiency, a factor in ecstasy related deaths?. British Journal of Clinical Pharmacology, 2002, 54, 69-70.	1.1	33
168	Warfarin and celecoxib interaction in the setting of cytochrome P450 (CYP2C9) polymorphism with bleeding complication. Postgraduate Medical Journal, 2004, 80, 107-109.	0.9	33
169	Pharmacogenomics of anticoagulants: steps toward personal dosage. Genome Medicine, 2009, 1, 10.	3.6	33
170	Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeaconÂ® probes. Clinica Chimica Acta, 2011, 412, 2063-2069.	0.5	33
171	Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?. Pharmaceutical Research, 2017, 34, 1564-1569.	1.7	33
172	A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. Journal of Hepatology, 2022, 76, 275-282.	1.8	33
173	Factors Affecting Drug Concentrations and QT Interval During Thioridazine Therapy. Clinical Pharmacology and Therapeutics, 2007, 82, 555-565.	2.3	32
174	Pharmacogenetics of Adverse Drug Reactions. Advances in Pharmacology, 2018, 83, 155-190.	1.2	32
175	Genetic Risk Factors in Drugâ€Induced Liver Injury Due to Isoniazidâ€Containing Antituberculosis Drug Regimens. Clinical Pharmacology and Therapeutics, 2021, 109, 1125-1135.	2.3	31
176	Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease. JHEP Reports, 2022, 4, 100477.	2.6	31
177	Nomenclature for alleles of the cytochrome P450 oxidoreductase gene. Pharmacogenetics and Genomics, 2009, 19, 565-566.	0.7	30
178	Flucloxacillin-induced liver injury. Toxicology, 2008, 254, 158-163.	2.0	29
179	Brief Report: Genetics of Alcoholic Cirrhosisâ€"<scp>G</scp>enom<scp>ALC</scp> Multinational Study. Alcoholism: Clinical and Experimental Research, 2015, 39, 836-842.	1.4	29
180	CYP2D6 and CYP2C19 genotypes of patients with terodiline cardiotoxicity identified through the yellow card system. British Journal of Clinical Pharmacology, 2000, 50, 77-80.	1.1	28

#	Article	IF	Citations
181	Quality of life in patients with venous thromboembolism and atrial fibrillation treated with coumarin anticoagulants. Thrombosis Research, 2015, 136, 69-75.	0.8	28
182	Candidate gene case-control studies. Pharmacogenomics, 2003, 4, 127-139.	0.6	27
183	Genotyping of the CYP 2D6 gene in Norwegian lung cancer patients and controls. Pharmacogenetics and Genomics, 1994, 4, 47???57.	5.7	26
184	A systematic review of costâ€“effectiveness analyses of pharmacogenetic-guided dosing in treatment with coumarin derivatives. Pharmacogenomics, 2010, 11, 989-1002.	0.6	26
185	Patatin-like phospholipase domain containing 3: A case in point linking genetic susceptibility for alcoholic and nonalcoholic liver disease. Hepatology, 2010, 51, 1463-1465.	3.6	26
186	A PDCD1 Role in the Genetic Predisposition to NAFLD-HCC?. Cancers, 2021, 13, 1412.	1.7	26
187	The biological activity of retinoids in melanoma cells. FEBS Letters, 1990, 273, 19-22.	1.3	25
188	Preempting and preventing drug-induced liver injury. Nature Genetics, 2010, 42, 650-651.	9.4	25
189	Obesity, Diabetes, Coffee, Tea, and Cannabis Use Alter Risk for Alcohol-Related Cirrhosis in 2 Large Cohorts of High-Risk Drinkers. American Journal of Gastroenterology, 2021, 116, 106-115.	0.2	25
190	CYP2C9 polymorphism and warfarin dose requirements. British Journal of Clinical Pharmacology, 2002, 53, 408-409.	1.1	24
191	Genetic Regulation of Warfarin Metabolism and Response. Seminars in Vascular Medicine, 2003, 03, 231-238.	2.1	24
192	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	3.2	24
193	Genotyping for Cytochrome P450 Polymorphisms. , 2006, 320, 193-208.		23
194	Valine-alanine manganese superoxide dismutase polymorphism is not associated with alcohol-induced oxidative stress or liver fibrosis. Hepatology, 2002, 36, 1355-1360.	3.6	23
195	Longâ€term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. Journal of Thrombosis and Haemostasis, 2012, 10, 606-614.	1.9	22
196	Association of metabolic gene polymorphisms with tobacco consumption in healthy controls. International Journal of Cancer, 2004, 110, 266-270.	2.3	21
197	The impact of simvastatin on warfarin disposition and dose requirements. Journal of Thrombosis and Haemostasis, 2006, 4, 1422-1424.	1.9	21
198	Relevance of Nonsynonymous CYP2C8 Polymorphisms to 13-cis Retinoic Acid and Paclitaxel Hydroxylation. Drug Metabolism and Disposition, 2010, 38, 1261-1266.	1.7	21

#	Article	IF	Citations
199	Warfarin dose requirement and CYP2C9 polymorphisms. Lancet, The, 1999, 353, 1972-1973.	6.3	20
200	The Relationship between PON1 Phenotype and PON1-192 Genotype in Detoxification of Three Oxons by Human Liver. Drug Metabolism and Disposition, 2007, 35, 315-320.	1.7	20
201	Human Leukocyte Antigen (HLA) Pharmacogenomic Tests: Potential and Pitfalls. Current Drug Metabolism, 2014, 15, 196-201.	0.7	20
202	Increased serum miR-193a-5p during non-alcoholic fatty liver disease progression: Diagnostic and mechanistic relevance. JHEP Reports, 2022, 4, 100409.	2.6	20
203	A polymorphic CfoI site in exon 6 of the human cytochrome P450 CYP2D6 gene detected by the polymerase chain reaction. Human Genetics, 1993, 91, 616-7.	1.8	19
204	Polymorphisms in Immunoregulatory Genes. Molecular Diagnosis and Therapy, 2002, 2, 13-23.	3.3	19
205	Genetic susceptibility in pancreatic ductal adenocarcinoma. British Journal of Surgery, 2007, 95, 22-32.	0.1	19
206	CYP2D6 update. Pharmacogenetics and Genomics, 2012, 22, 692-694.	0.7	19
207	N-Acetyltransferase (NAT2) Polymorphism and Breast Cancer Susceptibility: A Lack of Association in a Case-Control Study of Turkish Population. International Journal of Toxicology, 2004, 23, 25-31.	0.6	18
208	Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations. Drug Metabolism and Personalized Therapy, 2015, 30, 165-174.	0.3	18
209	Altered Tropomyosin Expression in Essential Hypertension. Hypertension, 2003, 41, 347-354.	1.3	17
210	Development of analytical technology in pharmacogenetic research. Naunyn-Schmiedeberg's Archives of Pharmacology, 2004, 369, 133-140.	1.4	17
211	Costâ€“effectiveness of pharmacogenetics in anticoagulation: international differences in healthcare systems and costs. Pharmacogenomics, 2012, 13, 1405-1417.	0.6	17
212	Relevance of CYP2E1 to Non-alcoholic Fatty Liver Disease. Sub-Cellular Biochemistry, 2013, 67, 165-175.	1.0	17
213	Efavirenz induced acute liver failure requiring liver transplantation in a slow drug metaboliser. Journal of Clinical Virology, 2013, 58, 331-333.	1.6	17
214	Is There a Need to Teach Pharmacogenetics?. Clinical Pharmacology and Therapeutics, 2014, 95, 245-247.	2.3	17
215	HLA associations with infliximab-induced liver injury. Pharmacogenomics Journal, 2020, 20, 681-686.	0.9	17
216	Peptide-based urinary monitoring of fibrotic nonalcoholic steatohepatitis by mass-barcoded activity-based sensors. Science Translational Medicine, 2021, 13, eabe8939.	5.8	17

#	Article	IF	Citations
217	Genome-wide association study identifies susceptibility loci for acute myeloid leukemia. Nature Communications, 2021, 12, 6233.	5.8	17
218	Deficient nifedipine oxidation: a rare inherited trait associated with cystic fibrosis kindreds. Pharmacogenetics and Genomics, 1992, 2, 19-24.	5.7	16
219	The kinetic mechanism of the major form of ox kidney aldehyde reductase with <scp>d</scp>-glucuronic acid. Biochemical Journal, 1982, 205, 381-388.	1.7	15
220	Characterization of the 16+9 kb and 30+9 kb CYP2D6 XbaI haplotypes. Pharmacogenetics and Genomics, 1997, 7, 149-152.	5.7	15
221	Analysis of Cytochrome P450 Polymorphisms. , 1998, 107, 405-422.		15
222	Role of UDP-Glucuronosyltransferase Isoforms in 13-cis Retinoic Acid Metabolism in Humans. Drug Metabolism and Disposition, 2010, 38, 1211-1217.	1.7	15
223	An evaluation of geneâ€“gene interaction between the CYP2C9 and VKORC1 genotypes affecting the anticoagulant effect of phenprocoumon and acenocoumarol. Journal of Thrombosis and Haemostasis, 2012, 10, 767-772.	1.9	15
224	Patients Benefit From Genetics-Guided Coumarin Anticoagulant Therapy. Clinical Pharmacology and Therapeutics, 2014, 96, 15-17.	2.3	15
225	Purification and properties of cellular retinoic acid-binding protein from neonatal rat skin. Biochimica Et Biophysica Acta - General Subjects, 1988, 965, 118-126.	1.1	14
226	Polymorphism in the Farnesyl Diphosphate Farnesyl Transferase 1 Gene and Nonalcoholic Fatty Liver Disease Severity. Gastroenterology, 2011, 140, 1694-1695.	0.6	14
227	Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDPâ€glucuronosyltransferases. British Journal of Pharmacology, 2011, 162, 989-999.	2.7	14
228	Genetic and Clinical Factors Are Associated With Statinâ€Related Myotoxicity of Moderate Severity: A Caseâ€“Control Study. Clinical Pharmacology and Therapeutics, 2018, 104, 178-187.	2.3	14
229	HLA DRB1*15:01-DQB1*06:02-Restricted Human CD4+ T Cells Are Selectively Activated With Amoxicillin-Peptide Adducts. Toxicological Sciences, 2020, 178, 115-126.	1.4	14
230	Contribution of CYP2C9 to variability in vitamin K antagonist metabolism. Expert Opinion on Drug Metabolism and Toxicology, 2006, 2, 3-15.	1.5	13
231	Evaluation of laboratory tests for cirrhosis and for alcohol use, in the context of alcoholic cirrhosis. Alcohol, 2018, 66, 1-7.	0.8	13
232	[24] Identification and analysis of retinoic acid-binding proteins and receptors from nuclei of mammalican cells. Methods in Enzymology, 1990, 189, 239-247.	0.4	12
233	Presenilin polymorphisms in Alzheimer's disease. Lancet, The, 1997, 350, 958-959.	6.3	12
234	Debrisoquine 4-hydroxylation (CYP2D6) polymorphism in Jordanians. Pharmacogenetics and Genomics, 1994, 4, 159-161.	5.7	11

#	Article	IF	Citations
235	The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects. British Journal of Clinical Pharmacology, 2000, 49, 240-243.	1.1	11
236	Family History of Cancer and Tobacco Exposure in Index Cases of Pancreatic Ductal Adenocarcinoma. Journal of Oncology, 2011, 2011, 1-7.	0.6	11
237	Cyclooxygenase-2 Polymorphisms and Pancreatic Cancer Susceptibility. Pancreas, 2011, 40, 1289-1294.	0.5	11
238	Transcriptional regulation of PNPLA3 and its impact on susceptibility to nonalcoholic fatty liver Disease (NAFLD) in humans. Aging, 2016, 9, 26-40.	1.4	11
239	Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury. Frontiers in Genetics, 2019, 10, 134.	1.1	10
240	Investigation of Oxidative Stress-Related Candidate Genes as Risk Factors for Drug-Induced Liver Injury due to Co-Amoxiclav. DNA and Cell Biology, 2020, 39, 349-354.	0.9	10
241	Warfarin sensitivity: be aware of genetic influence. Age and Ageing, 2003, 32, 226-227.	0.7	9
242	A rapid genotyping method for the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene. Journal of Thrombosis and Haemostasis, 2006, 4, 1158-1159.	1.9	9
243	Genotypes and phenotypes of CYP3A in Bangladeshi population. Clinica Chimica Acta, 2011, 412, 531-536.	0.5	9
244	Variants in the LGALS9 Gene Are Associated With Development of Liver Disease in Heavy Consumers of Alcohol. Clinical Gastroenterology and Hepatology, 2016, 14, 762-768.e1.	2.4	9
245	HLA-A*33:03-Restricted Activation of Ticlopidine-Specific T-Cells from Human Donors. Chemical Research in Toxicology, 2018, 31, 1022-1024.	1.7	9
246	Individualized drug therapy. Current Opinion in Drug Discovery & Development, 2007, 10, 29-36.	1.9	9
247	Genetic variants of hepatic transporters and susceptibility to drug induced liver injury. Toxicology, 2008, 253, 10.	2.0	8
248	Dosing algorithms for vitamin K antagonists across VKORC1 and CYP2C9 genotypes. Journal of Thrombosis and Haemostasis, 2017, 15, 465-472.	1.9	8
249	Kinetic Studies on the Major form of Aldehyde Reductase in ox Kidney: a General Kinetic Mechanism to Explain Substrate-Dependent Mechanisms and the Inhibition by Anticonvulsants. Journal of Enzyme Inhibition and Medicinal Chemistry, 1986, 1, 163-168.	0.5	7
250	Opportunities and limitations: the value of pharmacogenetics in clinical practice. British Journal of Clinical Pharmacology, 2014, 77, 583-586.	1.1	7
251	Genetic Polymorphisms Implicated in Nonalcoholic Liver Disease or Selected Other Disorders Have No Influence on Drugâ€Induced Liver Injury. Hepatology Communications, 2019, 3, 1032-1035.	2.0	7
252	Endocytosis and Lack of Cytotoxicity of Alkyl-Capped Silicon Quantum Dots Prepared from Porous Silicon. Materials, 2019, 12, 1702.	1.3	7

#	Article	IF	Citations
253	Molecular genotyping to predict debrisoquine hydroxylation phenotype. Lancet, The, 1990, 336, 889-890.	6.3	6
254	Reversal of warfarin-induced over-anticoagulation with individualised dosing of oral vitamin k: a pilot study. Journal of Thrombosis and Haemostasis, 2010, 8, 1123-5.	1.9	6
255	Polymorphisms in the Tropomyosin TPM1 Short Isoform Promoter Alter Gene Expression and Are Associated With Increased Risk of Metabolic Syndrome. American Journal of Hypertension, 2010, 23, 399-404.	1.0	5
256	Ageâ€stratified outcome of a genotypeâ€guided dosing algorithm for acenocoumarol and phenprocoumon. Journal of Thrombosis and Haemostasis, 2017, 15, 454-464.	1.9	4
257	Pharmacogenomics spotlight commentary: From the United Kingdom to global populations. British Journal of Clinical Pharmacology, 2021, 87, 4546-4548.	1.1	4
258	Pharmacogenetics of oral anticoagulants. Personalized Medicine, 2005, 2, 23-27.	0.8	3
259	A Genome-Wide Association Study Identifies Potential Susceptibility Loci for Hepatotoxicity Due to Various Drugs. Gastroenterology, 2011, 140, S-886.	0.6	3
260	TM6SF2 as a genetic risk factor for fibrosis. Hepatology, 2015, 62, 1321-1321.	3.6	3
261	The Effect of the CYP1A1*2A Allele on Colorectal Cancer Susceptibility in a British Population. Genetic Testing and Molecular Biomarkers, 2016, 20, 475-477.	0.3	3
262	Pharmacogenomics of Drug-Induced Liver Injury. Advances in Molecular Pathology, 2020, 3, 107-115.	0.2	3
263	Identification of susceptible HLA class II coâ€amoxiclav genotypes based on the analysis of drugâ€specific Tâ€cells from patients with liver injury. Clinical and Translational Allergy, 2014, 4, O3.	1.4	2
264	Comparison of dosing algorithms for acenocoumarol and phenprocoumon using clinical factors with the standard care in the Netherlands. Thrombosis Research, 2015, 136, 94-100.	0.8	2
265	Nuclear Retinoic-Acid-Binding Proteins and Receptors in Retinoic-Acid-Responsive Cell Lines. Pathobiology, 1989, 57, 339-345.	1.9	1
266	New Opportunities in Cancer Risk Evaluation Using PCR-Based DNA Analysis for CYP2D6. Environmental Health Perspectives, 1993, 101, 117.	2.8	1
267	Pharmacogenetics of cytotoxic drugs. Expert Review of Anticancer Therapy, 2001, 1, 301-308.	1.1	1
268	Human Leukocyte Antigen (HLA) and Other Genetic Risk Factors in Drug-Induced Liver Injury (DILI). Methods in Pharmacology and Toxicology, 2018, , 497-509.	0.1	1
269	[31] Cellular retinoic acid-binding protein from neonatal rat skin: Purification and analysis. Methods in Enzymology, 1990, 189, 307-314.	0.4	0
270	CYP3A5 phenotype-genotype correlations in a British population. British Journal of Clinical Pharmacology, 2004, 57, 664-664.	1.1	0

#	Article	IF	Citations
271	Relevance of PXR to Flucloxacillin-induced Liver Injury. Toxicology, 2008, 253, 2.	2.0	0
272	Pharmacogenomics Applications in Drug Metabolism. Methods in Pharmacology and Toxicology, 2008, , 109-120.	0.1	0
273	Institutional Profile: Pharmacogenomics research at Newcastle University. Pharmacogenomics, 2012, 13, 1333-1338.	0.6	0
274	Genetic Factors in the Pathogenesis of Drug-Induced Liver Injury. , 2013, , 215-225.		0
275	Pharmacogenomics of Warfarin. , 2014, , 497-507.		0
276	Direct-to-consumer pharmacogenomic testing assessed in a US-based study. Journal of the Royal College of Physicians of Edinburgh, The, 2014, 44, 212-213.	0.2	0
277	Characterization of amoxicillin and clavulanicâ€acidâ€responsive CD4+ And CD8+ Tâ€cells in patients with coâ€amoxiclavâ€induced liver injury. Clinical and Translational Allergy, 2014, 4, P42.	1.4	0
278	Point of care testing for improving risk- benefit ratio of aspirin and warfarin. Molecular Cytogenetics, 2014, 7, I54.	0.4	0
279	Drug-Induced Cholestasis: Mechanisms and Importance. , 2017, , 117-128.		0
280	Genetic risk factors for DILI-recent findings from large international networks. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY76-2.	0.0	0